Open access
Open access
Powered by Google Translator Translator

RCT: In patients with immune-mediated inflammatory diseases (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn disease, or psoriasis) treated with Infliximab, a proactive therapeutic drug monitoring protocol was more likely to lead to sustained disease control.

14 Jan, 2022 | 07:57h | UTC

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.